SavedAdd your journal

Journals / Acta Medica Nicomedia / 2022 / Cilt: 5 - Sayı: 2

Evaluation of miR-145 and miR-146a as potential biomarkers for diagnosis of Myelodysplastic Syndrome

Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

Seda SÜSGÜN
Onur BAYKARA
Emrah YÜCESAN
R. Dilhan KURU
Başak ASLANELİ ÇAKMAK
Ayşegül YABACI
Şeniz ÖNGÖREN
Ayhan DEVİREN
Yelda TARKAN ARGÜDEN
Pages
61–66
Publication Date
2022-06-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Cytogenetic examination revealed clonal cytogenetic abnormalities in 43.4% of cases. miR-146a decreased in 23 of 24 patients regardless of chromosome 5 abnormalities (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic stem cell disorders characterized by ineffective hematopoiesis, bone marrow dysplasia, and peripheral cytopenias. microRNAs (miRNAs) are small non-coding RNAs that play key roles in post-transcriptional regulation of gene expression and have been determined potential in disease diagnostics and therapeutics owing to their stability.
📊
Key Findings & Data:Recent evidence suggests that haploinsufficiency of the miR-145 and miR-146a, encoded from 5q Common Deleted Region (CDR) may contribute to the phenotype in MDS.
💡
Conclusion & Impact:Results: Cytogenetic examination revealed clonal cytogenetic abnormalities in 43.4% of cases. miR-146a decreased in 23 of 24 patients regardless of chromosome 5 abnormalities (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Miyelodisplastik sendrom · tanısal biyobelirteç · miR-146a

Abstract

Objective: Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic stem cell disorders characterized by ineffective hematopoiesis, bone marrow dysplasia, and peripheral cytopenias. microRNAs (miRNAs) are small non-coding RNAs that play key roles in post-transcriptional regulation of gene expression and have been determined potential in disease diagnostics and therapeutics owing to their stability. Recent evidence suggests that haploinsufficiency of the miR-145 and miR-146a, encoded from 5q Common Deleted Region (CDR) may contribute to the phenotype in MDS. Although, interstitial del(5q) is the most common chromosomal abnormality in MDS, these findings are inconsistent in Turkish patients. Therefore, we aimed to investigate assess the diagnostic value of miR-145/miR-146a and their relation with del(5q) or monosomy 5 in MDS. Methods: In order to determine the association between del(5q) and expression miR-145/miR-146a, conventional cytogenetics (CC), FISH, and qRT-PCR methods were performed for 24 patients with MDS and 20 healthy individuals. Additionally, ROC curves were generated to evaluate putative diagnostic value of miRNAs. Results: Cytogenetic examination revealed clonal cytogenetic abnormalities in 43.4% of cases. miR-146a decreased in 23 of 24 patients regardless of chromosome 5 abnormalities (p

Özet

Amaç: Miyelodisplastik sendrom (MDS), verimsiz hematopoez, kemik iliği displazisi ve periferik sitopeni ile karakterize edilen heterojen bir grup hematopoetik kök hücre bozukluğudur. mikroRNA'lar (miRNA'lar), gen ifadesinin post-transkripsiyonel düzenlenmesinde kilit rol oynayan küçük kodlamayan RNA’lardır ve stabiliteleri sayesinde hastalık tanısında ve tedavisinde potansiyelleri belirlenmiştir. Son çalışmalar, 5q Yayın Delesyon Bölgesi’nden (YDB) kodlanan miR-145 ve miR-146a'nın haplo-yetmezliğinin MDS'deki fenotipe katkıda bulunabileceğini düşündürmektedir. MDS'de en sık gözlenen kromozom anomalisi interstisyel del(5q) olmasına rağmen, bu bulgular Türkiye popülasyonundaki örnekler ile tutarsızdır. Bu nedenle, MDS'de miR-145/miR-146a'nın tanısal kullanım değerini ve bu miRNA’ların del(5q) ve/veya monozomi 5 ile ilişkisini değerlendirmeyi amaçladık. Yöntem: del(5q) ile miR-145/miR-146a ekspresyonu arasındaki ilişkiyi belirlemek için MDS'li 24 hasta ve 20 sağlıklı kontrol için konvansiyonel sitogenetik (CC), FISH ve qRT-PCR yöntemleri uygulanmıştır. Ek olarak, miRNA'ların tanısal değerini değerlendirmek için ROC eğrileri oluşturulmuştur. Bulgular: Sitogenetik incelemeler, vakaların %43,4'ünde klonal sitogenetik anomali olduğunu gösterdi. miR-146a ifadesi, 5. kromozom anomalilerinden bağımsız olarak 24 hastanın 23'ünde azalmaktaydı (p

🔖

Cite This Article

SÜSGÜN, S., BAYKARA, O., YÜCESAN, E., KURU, R. D., ÇAKMAK, B. A., YABACI, A., ÖNGÖREN, Ş., DEVİREN, A., ARGÜDEN, Y. T. (2022). Evaluation of miR-145 and miR-146a as potential biomarkers for diagnosis of Myelodysplastic Syndrome. Acta Medica Nicomedia, Cilt: 5 - Sayı: 2, 61–66. https://ajindex.com/articles/449980

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Campbell LJ. Cancer cytogenetics: methods and protocols. Humana Press; 2011
  2. Garcia-Manero G. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(1):97-108
  3. Zahid MF, Malik UA, Sohail M, Hassan IN, Ali S, Shaukat MHS. Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview. Int J Hematol Oncol Stem Cell Res. 2017;11(3):231-239
  4. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7(2):118-129
  5. Charles Wiener M, Kasper DL, Fauci AS, et al. Harrison's Principles of Internal Medicine Self-Assessment and Board Review. 2012
  6. Hoffman R, Benz Jr EJ, Silberstein LE, Heslop H, Anastasi J, Weitz J. Hematology: basic principles and practice. Elsevier Health Sciences; 2013
  7. Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol. 2008;142(5):695-708
  8. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395
  9. Kawankar N, Vundinti BR. Cytogenetic abnormalities in myelodysplastic syndrome: an overview. Hematology. 2011;16(3):131-138
  10. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12(1):5-10
  11. Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014;49(4):216-227
  12. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58
  13. McGowan-Jordan J. ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016): Recommendations of the International Standing Committee on Human Cytogenomic Nomenclature Including New Sequence-based Cytogenetic Nomenclature Developed in Collaboration with the Human Genome Variation Society (HGVS) Sequence Variant Description Working Group. Karger; 2016
  14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408
  15. Wang J, Zhu X, Xiong X, et al. Identification of potential urine pro